🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Kidney injury in patients with heart failure-related cardiogenic shock: Results from an international, multicentre cohort study onlinelibrary.wiley.com/doi/10.1002/ej… #EJHF European Society of Cardiology Journals Henry Han Amr Abdin Giuseppe Galati

White paper on advancing #implementation of #CKM therapies led by Nkiru Osude, MD MS Christopher Granger et al in AmericanHeartJ Wonderful to see seasoned implementation scientists or investigators who’ve led high-touch implementation RCTs / projects on author panel. sciencedirect.com/science/articl…

The role of finerenone in the concomitant management of CKD-type 2 diabetes and the implication for HF prevention and treatment finerenone presents new evidence-based therapy for HFpEF/HFmrEF in addition to current application in CKD associated with T2D link.springer.com/article/10.100…

Presented at #ERA25: In the CONFIDENCE trial in persons with chronic kidney disease and type 2 diabetes, combination therapy with finerenone and empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alone. Full trial results:

🔥 #CONFIDENCE in NEJM Simultaneous initiation of #SGLT2i + #nsMRA safely and rapidly delivers in patients with CKD & T2D A new age of combination therapies has arrived in #CKM care #ERA25 nejm.org/doi/full/10.10…

The CONFIDENCE trial 64% of patients achieved >40% reduction in UACR with simultaneous initiation of finerenone and SGLTi

The CONFIDENCE trial Primary efficacy endpoints met for combination: 32% greater reduction vs empagliflozin 29% greater reduction vs finerenone

In the CONFIDENCE trial in persons with chronic kidney disease and type 2 diabetes, combination therapy with finerenone and empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alon nejm.org/doi/full/10.10…

Special focus issue in JACC Journals this week on Cardiac Amyloidosis. Many important articles! Sharing my editorial with Joban Vaishnav from Johns Hopkins University sciencedirect.com/journal/journa…

Advances in the screening, diagnosis, and treatment of transthyretin amyloid cardiomyopathy: New insights and future directions Latest review article with my colleagues Drs. Andrew Girard and Talal Asif pubmed.ncbi.nlm.nih.gov/40147532/

Fantastic to see CONFIDENCE trial results presented at #ERA25 and in NEJM Prevention of CV events, esp. heart failure, is probably most compelling rationale for rapid initiation of combo therapy in CKD/T2D, with benefits on kidney failure accruing gradually over time

#CONFIDENCE built-in randomized withdrawal phase (after 180d of therapy) Reassuringly, early effects of combination therapy on: hemodynamics (BP lowering) electrolytes (K+ increase) kidney function (eGFR “dip”) all rapidly & fully reversible after drug cessation in just 30d!

The first question to ask when reviewing a paper is whether it is a blog or a peer-reviewed scientific publication 🙃

🚀 Greatful to see JACC Journals highlight our PREEMPT-HF study in editorial by DeVore and Anu Lala-Trindade 🔹 2,155 pts / 103 sites across 4 continents 🔹 HeartLogic alerts help identify patients with residual congestion at/after discharge Next step: embed these insights into

#CONFIDENCE Safer Together 🤝🏾 Starting upfront combination of #SGLT2i empagliflozin & #nsMRA finerenone leads to lower risks of clinically relevant hyperkalemia than starting finerenone alone. Magnitude of protection (~15-20%) well aligned w prior data ahajournals.org/doi/10.1161/CI…

#CONFIDENCE results: now explore HF #CONFIRMATION-HF, we enrolled 12th patient Saint Luke's Mid America Heart Institute today! Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF) | ClinicalTrials.gov

Results of the Precision Event Monitoring for Patients With Heart Failure Using HeartLogic Study (PREEMPT-HF) HeartLogic index trends were significantly different for patients who were readmitted for HF jacc.org/doi/10.1016/j.…

Changes in Serum K , #SBP , #eGFR , and #HbA1c at Various Time Points NEJM